Moderna ties up with Immatics to boost cancer vaccine development
Send a link to a friend
[September 12, 2023]
(Reuters) -Moderna said on Monday it has struck a deal with
German drug developer Immatics for developing cancer vaccines and
therapies, and would pay $120 million in cash and additional milestone
payments.
Moderna said the companies would use Immatics' drug discovery platform
to develop mRNA-based cancer vaccines, and also study its own cancer
vaccine for use in combination with Immatics' cancer therapy IMA203.
The deal is the latest in Moderna's push to expand beyond COVID as
demand for the shots falls dramatically, and develop a vaccine for
cancer, a dream that scientists have chased for decades with little
success.
Moderna is already developing a cancer vaccine with Merck, which was
shown to cut the risk of recurrence or death by 44% in patients with
deadly skin cancer melanoma, in a mid-stage trial. It also has vaccines
under development for flu and respiratory syncytial virus (RSV), among
others.
Under the terms of collaboration, Moderna will lead the development and
commercialization of the cancer vaccines resulting from the
collaboration, while Immatics will be responsible for pre-clinical and
potential early-stage studies.
[to top of second column]
|
![](../images/091223PIX/health32.jpg)
Syringes with needles are seen in front of a displayed Moderna logo
in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File
Photo
![](http://archives.lincolndailynews.com/2019/Sep/05/images/ads/current/stclara_lda_SPONSOR_090519.png) Immatics will also receive research
funding and is eligible for development, regulatory, and commercial
milestone payments that could exceed $1.7 billion, Moderna said.
Immatics' U.S.-listed shares were up about 7% at $13 before the
bell.
(Reporting by Christy Santhosh in Bengaluru; Editing by Anil D'Silva
and Shounak Dasgupta)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |